ATOSSA THERAPEUTICS, INC.
Datakwaliteit: 83%
ATOS
Nasdaq
Manufacturing
Chemicals
€ 4,91
▲
€ 0,09
(1,87%)
Marktkapitalisatie: 42,28 M
Prijs
€ 4,91
Marktkapitalisatie
42,28 M
Dagbereik
€ 4,73 — € 5,05
52-Weeksbereik
€ 3,76 — € 19,35
Volume
36.445
Openen € 4,84
50D / 200D Gem.
€ 5,39
8,97% below
50D / 200D Gem.
€ 10,51
53,28% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -29,79 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-64,70%
Onder sectorgemiddelde (-53,41%)
ROIC-54,60%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio6,77
Interest CoverageN/A
Waardering
PE (TTM)
-1,22
Boven sectorgemiddelde (-1,48)
P/B Ratio0,85
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,2 | -1,5 |
| P/B | 0,9 | 1,6 |
| ROE % | -64,7 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -34,77 M |
| ROE | -64,70% | ROA | -56,75% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -29,79 M |
| ROIC | -54,60% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 6,77 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 47,45 M | Tangible Book Value | 49,79 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,22 | Forward P/E | N/A |
| P/B Ratio | 0,85 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -70,44% | ||
| Market Cap | 42,28 M | Enterprise Value | -9,56 M |
| Per Share | |||
| EPS (Diluted TTM) | -4,04 | Revenue / Share | N/A |
| FCF / Share | -3,46 | OCF / Share | -3,46 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 85,66% |
| SBC-Adj. FCF | -32,68 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -34,77 M | -25,50 M | -30,09 M | -26,96 M | -20,61 M |
| EPS (Diluted) | -4,04 | -0,20 | -0,24 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -37,14 M | -27,62 M | -31,38 M | -27,69 M | -20,52 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 21,19 M | 14,12 M | 17,33 M | 15,08 M | 9,21 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | 8.000,0 | 23.000,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 47,61 M | 76,44 M | 96,25 M | 123,53 M | 141,26 M |
| Total Liabilities | 8,26 M | 4,97 M | 5,24 M | 5,57 M | 3,13 M |
| Shareholders' Equity | 39,35 M | 71,48 M | 91,02 M | 117,96 M | 138,14 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 41,30 M | 71,08 M | 88,46 M | 110,89 M | 136,38 M |
| Current Assets | 45,62 M | 74,46 M | 92,22 M | 118,20 M | 141,24 M |
| Current Liabilities | 8,26 M | 4,97 M | 5,24 M | 5,57 M | 3,13 M |
{"event":"ticker_viewed","properties":{"ticker":"ATOS","listing_kind":"stock","pathname":"/stocks/atos","exchange":"Nasdaq","country":"US"}}